Amol Akhade, Senior Consultant at Fortis Hospitals Mumbai, shared a post on X:
“Trials to Watch – WCLC 2025
Plenary LBAs:
FLAURA2: Osimertinib + Chemo (OS update)
Aumolertinib + Chemo (EGFRm NSCLC)
HARMONi-A: Ivonescimab + Chemo vs Chemo
ARROS-1: Zidesamtinib (ROS1+)
CheckMate 816: Neoadjuvant Nivolumab (OS)
EA5181: Durvalumab + CRT in Stage III
NADIM Adjuvant: Nivolumab + Chemo
Oncology is moving fast—practice-changing data ahead!”
Drew Moghanaki, Chief Medical Officer at Respirati, shared a post by Amol Akhade, adding:
“EA5181: a phase III RCT comparing concurrent CRT+Durva vs PACIFIC for clinical stage III NSCLC. Thank you Nathan A. Pennell and John Varlotto for your stalwart leadership completing this NCI sponsored study.”
